系统的生物信息学分析确定了什科宁作为一种新型的mTOR通路抑制剂,用于三阴性乳腺癌的进展
Wenna Liu1, Qingqing Liu1, Jingyue Yao1
1Precision Pharmacy and Drug Development Center, Department of Pharmacy, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China.
Frontiers in pharmacology
|September 15, 2025
概括
石康宁是一种天然化合物,有效地抑制了三阴性乳腺癌 (TNBC) 细胞的生长和迁移. 它针对mTOR信号通路,为这种具有挑战性的癌症亚型提供了一个有希望的新治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 三重阴性乳腺癌 (TNBC) 由于治疗耐药性和患者的治疗结果不佳而带来了重大治疗挑战.
- 在TNBC中观察到的shikonin抗瘤作用背后的分子机制需要阐明.
研究的目的:
- 系统地评估shikonin在三阴性乳腺癌中的抗瘤作用和分子机制.
- 通过检查其与mTOR信号通路的相互作用来研究shikonin作为向治疗的潜力.
主要方法:
- 用殖民地形成和伤口愈合测试来评估细胞增殖和迁移.
- 转录形状分析被用来识别shikonin治疗后的分子变化.
- 进行了分子对接模拟,以预测shikonin和mTOR蛋白之间的结合相互作用.
主要成果:
- 石康宁显著抑制了TNBC细胞的增殖和迁移.
- 转录组分析显示,关键的mTOR通路基因 (MTOR,CCND1,CDK6) 的下调.
- 分子对接证实了什科宁与mTOR蛋白直接结合,表明该途径受阻.
结论:
- 石康宁通过抑制mTOR信号通路,对TNBC表现出强大的抗瘤活性.
- 这些发现表明shikonin是TNBC治疗的潜在天然mTOR抑制剂,解决目前治疗方法的局限性.
- 对于这种侵袭性乳腺癌亚型,需要对石康宁的治疗应用进行进一步的研究.
更多相关视频
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
8.3K
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.5K
相关概念视频
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:22PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:20The JAK-STAT Signaling Pathway
12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.1K